苏州无限医疗完成数亿元A轮融资，高特佳领投

Company Overview - Infinity Neuro, a medical device company focused on innovative solutions for neurovascular surgery, has completed a Series A financing round of several hundred million RMB, led by Gaotejia with participation from multiple institutions [1] - The company specializes in the research, production, and commercialization of medical devices in the cerebrovascular field, addressing unmet clinical needs in neurointervention [1] Product Development - The core product, HUB navigation-assisted reperfusion system, is a global first and has significantly reduced the thrombectomy time in traditional interventional surgeries to around 10 minutes, marking a breakthrough in the field of ischemic stroke intervention [2] - The first product, Inspira aspiration catheter, received CE certification under the new EU MDR regulations in January 2023 and is the first neurovascular device approved in Europe under these new rules [2] Market Strategy - Infinity Neuro aims to accelerate the clinical research and global commercialization of its core product through the recent financing, focusing on a dual-engine strategy of globalization and branding [2] - The company has established sales channels in various countries including China, the USA, Western Europe, India, and Brazil, leveraging a global perspective to create differentiated competitive advantages [2] Investment Insights - Investors see significant opportunities in the neurointervention sector, with the potential for domestic replacement and international expansion, as Infinity Neuro is one of the few teams with an international background [2] - The company’s innovative product lineup, developed around clinical pain points, is expected to provide substantial clinical value and address the growing clinical demand driven by an aging population and improved living standards [2]